Nuformix (FRA:1RT) Buyback Yield %: -30.89 (As of Jul. 07, 2026)


What is Nuformix Buyback Yield %?

Nuformix FRA:1RT Buyback Yield % is -30.89 as of Jul. 07, 2026. The stock has 1 warning sign investors should review. Among 740 Biotechnology companies, Nuformix ranks worse than 77.43% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Nuformix's current buyback yield was -30.89%.

Nuformix Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Nuformix's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuformix Buyback Yield % Chart

Nuformix Annual Data
Trend Dec15 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Sep24 Sep25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -23.51 -4.44 -71.44 -42.91 -39.22

Nuformix Semi-Annual Data
Dec15 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.46 -30.47 -29.60 -14.76 -32.90

FRA:1RT vs VRTX, REGN, ALNY: Buyback Yield % Comparison

For the Biotechnology subindustry, Nuformix's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuformix Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuformix's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Nuformix's Buyback Yield % falls into.


Nuformix Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Nuformix's Buyback Yield for the fiscal year that ended in Sep. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0.797) / 2.032328
=-39.22%

Nuformix's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 1.673) / 1.3048745
=-128.21%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -30.89 mean?
Nuformix (FRA:1RT) has a Buyback Yield % of -30.89 as of Jul. 07, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Nuformix and its competitors. According to the industry distribution chart, Nuformix ranks #573 out of 740 companies in the Biotechnology industry, placing it in the top 77.4%.
Is Nuformix's Buyback Yield % too high?
Nuformix's current Buyback Yield % is -30.89. Based on the distribution chart, Nuformix ranks #573 out of 740 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Nuformix's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nuformix ranks #573 out of 740 companies for Buyback Yield %. This places Nuformix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Nuformix and its competitors. Nuformix's current Buyback Yield % is -30.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuformix stock overvalued right now?
Nuformix (FRA:1RT) has a current Buyback Yield % of -30.89. The current Buyback Yield % is -30.89. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Nuformix (FRA:1RT), the current Buyback Yield % is -30.89 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nuformix Business Description

Other Exchanges NFX:UK1RT:Germany
Address C/O Arch Law Limited, 8 Bishopsgate, Huckletree Bishopsgate, London, GBR, EC2N 4BQ
Nuformix PLC is a pharmaceutical development company. It operates in pharmaceutical development, targeting unmet medical needs in fibrosis and oncology through drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.